---
title: "\"Performance\" STARCOIN GROUP reports a mid-term loss of 116 million yuan, turning from profit to loss"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/267972325.md"
description: "STARCOIN GROUP announced its interim results for the six months ending in September, with revenue of HKD 3.21 million, an increase of 5.8% year-on-year. It recorded a loss of HKD 116 million, compared to a net profit of HKD 102 million in the same period last year, turning from profit to loss; loss per share was HKD 0.0597. No dividend was declared"
datetime: "2025-11-30T11:49:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/267972325.md)
  - [en](https://longbridge.com/en/news/267972325.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/267972325.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/267972325.md) | [繁體中文](https://longbridge.com/zh-HK/news/267972325.md)


# "Performance" STARCOIN GROUP reports a mid-term loss of 116 million yuan, turning from profit to loss

STARCOIN GROUP (00399.HK) announced its interim results for the six months ending in September, with revenue of HKD 3.21 million, an increase of 5.8% year-on-year. It recorded a loss of HKD 116 million, compared to a net profit of HKD 102 million in the same period last year, turning from profit to loss; the loss per share was HKD 0.0597. No dividend was declared

### Related Stocks

- [STARCOIN GROUP (00399.HK)](https://longbridge.com/en/quote/00399.HK.md)

## Related News & Research

- [AUB Group Cancels 127,559 Lapsed Performance Share Rights](https://longbridge.com/en/news/281329231.md)
- [Global's Top 3 Dividend Stocks To Consider](https://longbridge.com/en/news/281341240.md)
- [PetroChina Renews Financial Deal With Related Company](https://longbridge.com/en/news/280998322.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/en/news/281325910.md)
- [Osl Group FY adjusted non-IFRS income HK$534.1 million](https://longbridge.com/en/news/281223382.md)